Your browser is no longer supported. Please, upgrade your browser.
EPZM Epizyme, Inc. daily Stock Chart
EPZM [NASD]
Epizyme, Inc.
Index- P/E- EPS (ttm)-1.61 Insider Own0.20% Shs Outstand91.59M Perf Week-2.80%
Market Cap1.62B Forward P/E- EPS next Y-2.01 Insider Trans-46.41% Shs Float76.76M Perf Month16.06%
Income-139.80M PEG- EPS next Q-0.51 Inst Own98.00% Short Float10.21% Perf Quarter45.28%
Sales29.20M P/S55.55 EPS this Y21.30% Inst Trans1.16% Short Ratio10.48 Perf Half Y42.59%
Book/sh2.82 P/B6.28 EPS next Y-6.90% ROA-40.10% Target Price20.63 Perf Year200.17%
Cash/sh3.20 P/C5.54 EPS next 5Y38.00% ROE-50.40% 52W Range5.14 - 19.30 Perf YTD187.50%
Dividend- P/FCF- EPS past 5Y-50.90% ROI-55.00% 52W High-8.24% Beta2.53
Dividend %- Quick Ratio10.90 Sales past 5Y-20.50% Gross Margin- 52W Low244.55% ATR0.91
Employees124 Current Ratio10.90 Sales Q/Q- Oper. Margin- RSI (14)64.13 Volatility5.02% 4.67%
OptionableYes Debt/Eq0.00 EPS Q/Q26.50% Profit Margin- Rel Volume0.74 Prev Close17.81
ShortableYes LT Debt/Eq0.00 EarningsJan 29 BMO Payout- Avg Volume747.78K Price17.71
Recom1.40 SMA206.49% SMA5029.87% SMA20037.46% Volume553,590 Change-0.56%
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-10-16Reiterated Mizuho Buy $20 → $18
Apr-05-16Initiated Citigroup Buy $17
Mar-14-16Upgrade H.C. Wainwright Neutral → Buy $25
Mar-10-16Reiterated Wedbush Outperform $33 → $22
Mar-10-16Reiterated Mizuho Buy $26 → $20
Mar-09-16Reiterated RBC Capital Mkts Outperform $39 → $26
Aug-06-15Reiterated Mizuho Buy $29 → $26
Jul-20-15Downgrade H.C. Wainwright Buy → Neutral $45 → $22
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Dec-15-19 03:49PM  The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week Benzinga
Dec-12-19 11:56AM  The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM  5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-10-19 07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-07-19 10:05AM  Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma Business Wire
Dec-06-19 07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga +19.08%
Dec-03-19 03:18PM  Epizyme Announces FDA Committee Review of Tazemetostat NDA Zacks
08:54AM  Implied Volatility Surging for Epizyme (EPZM) Stock Options Zacks
Dec-02-19 10:45AM  Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma Business Wire
Nov-28-19 10:00AM  Epizyme (EPZM) Is Up 6.9% in One Week: What You Should Know Zacks
Nov-26-19 09:38AM  Epizyme, Inc. (EPZM) Shares March Higher, Can It Continue? Zacks
Nov-07-19 06:08AM  These 36 Mass. firms made Deloitte's Technology Fast 500 American City Business Journals +6.59%
Nov-05-19 08:00AM  Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme PR Newswire +18.46%
Nov-04-19 07:00AM  Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement Business Wire +5.15%
Oct-30-19 07:55AM  Epizyme (EPZM) Reports Q3 Loss, Tops Revenue Estimates Zacks +9.57%
06:30AM  Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results Business Wire
Oct-27-19 02:02PM  Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) Insider Monkey
Oct-15-19 08:37AM  We're Hopeful That Epizyme (NASDAQ:EPZM) Will Use Its Cash Wisely Simply Wall St.
Sep-08-19 09:30AM  Epizyme (EPZM) Up 7% Since Last Earnings Report: Can It Continue? Zacks
Sep-04-19 06:30AM  Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth Business Wire
Aug-29-19 06:30AM  Epizyme to Participate in Upcoming September Conferences Business Wire +5.80%
Aug-16-19 12:32PM  How Should Investors Feel About Epizyme, Inc.'s (NASDAQ:EPZM) CEO Pay? Simply Wall St. +6.94%
Aug-15-19 09:17AM  Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat Zacks
Aug-12-19 08:37AM  Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates Zacks
Aug-09-19 07:55AM  Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates Zacks -5.66%
06:30AM  Epizyme Reports Business Progress and Second Quarter 2019 Results Business Wire
Aug-08-19 10:45AM  Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 Zacks
10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
09:26AM  Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates Zacks
Aug-06-19 06:30AM  Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference Business Wire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-25-19 10:33AM  Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for Zacks
06:30AM  Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma Business Wire
Jul-22-19 06:30AM  Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer Business Wire
Jul-12-19 04:53PM  Here's Why Epizyme Rose 103.7% in the First Half of 2019 Motley Fool
Jun-24-19 05:53PM  Epizyme Announces Positive Interim Data on Lead Candidate Zacks
Jun-21-19 07:45AM  Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma Business Wire +10.81%
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-12-19 06:30AM  Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data Business Wire -13.76%
Jun-11-19 06:57PM  Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) Insider Monkey
Jun-05-19 09:30AM  Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report? Zacks
Jun-03-19 06:30AM  Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting Business Wire
May-31-19 10:46AM  Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure Zacks
05:57AM  Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition American City Business Journals
May-30-19 06:30AM  Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma Business Wire
05:51AM  Will Epizyme to Surge Higher? Zacks
May-29-19 06:30AM  Epizyme to Present at Jefferies 2019 Healthcare Conference Business Wire
May-28-19 09:02AM  Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why? Zacks
May-16-19 09:33AM  Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings Business Wire +7.50%
May-09-19 08:10PM  Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) Insider Monkey
May-06-19 07:45AM  Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:35AM  Epizyme: 1Q Earnings Snapshot Associated Press
06:30AM  Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results Business Wire
Apr-22-19 03:42PM  If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today Simply Wall St.
Mar-28-19 09:30AM  Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report? Zacks
Mar-12-19 10:45AM  Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-08-19 12:14PM  Does Epizyme, Inc.s (NASDAQ:EPZM) CEO Salary Compare Well With Others? Simply Wall St.
Mar-06-19 10:16PM  Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock Business Wire
04:01PM  Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock Business Wire
Mar-05-19 06:30AM  Epizyme Announces Presentations at Upcoming March Investor Conferences Business Wire
Mar-01-19 06:41AM  Edited Transcript of EPZM earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 10:14AM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4 Zacks
Feb-26-19 06:30AM  Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire +12.05%
Feb-19-19 06:30AM  Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference Business Wire -5.51%
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
Feb-12-19 07:35AM  New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-07-19 06:14PM  Epizyme to File NDA for Tazemetostat in Follicular Lymphoma Zacks +5.79%
Jan-04-19 04:27PM  Why GameStop, Novavax, and Epizyme Jumped Today Motley Fool +32.78%
02:13PM  Here's Why Epizyme's Shares Are Surging 19.6% Higher Today Motley Fool
10:10AM  These 4 Healthcare Stocks Are Making Moves ACCESSWIRE
06:30AM  Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance Business Wire
Dec-19-18 10:44PM  Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds? Insider Monkey
Dec-18-18 06:30AM  Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor Business Wire
Dec-02-18 09:30AM  Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report? Zacks
Nov-15-18 06:35AM  Epizyme Announces Conference Call to Discuss Corporate Updates Business Wire
Nov-09-18 08:00AM  Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-05-18 02:20PM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3 Zacks
Nov-02-18 07:40AM  Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates Zacks -6.29%
06:35AM  Epizyme: 3Q Earnings Snapshot Associated Press
06:30AM  Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress Business Wire
Oct-22-18 05:00AM  Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO Business Wire -5.48%
Oct-18-18 01:28PM  What Kind Of Investor Owns Most Of Epizyme Inc (NASDAQ:EPZM)? Simply Wall St.
Oct-17-18 07:45AM  Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -5.86%
Oct-12-18 05:00AM  Big Biotech Investors Poured $29 Million Into 2 Battered Companies Barrons.com
Oct-10-18 06:45AM  Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO Business Wire
Oct-05-18 04:05PM  Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-03-18 07:54AM  The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares Benzinga
Oct-02-18 05:00PM  After-hours buzz: TPX, JCP & more CNBC -6.99%
04:01PM  Epizyme Announces Proposed Public Offering of Common Stock Business Wire
Sep-25-18 10:52AM  FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study Zacks
Sep-24-18 07:45AM  Epizyme's stock soars after FDA lifts hold on trial enrollments MarketWatch
06:30AM  Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program Business Wire
Aug-29-18 07:00AM  Epizyme to Participate in Upcoming Investor Conferences Business Wire
Aug-20-18 07:30AM  Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-05-18 11:28PM  Edited Transcript of EPZM earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-03-18 05:34PM  Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks Zacks
Aug-02-18 10:20AM  Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates Zacks -23.85%
10:07AM  Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss Zacks
09:18AM  Epizyme: 2Q Earnings Snapshot Associated Press
07:00AM  Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates Business Wire
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOTT DAVID MDirectorJun 27Sale12.4352,473652,1340Jun 28 07:05 PM
MOTT DAVID MDirectorJun 26Sale12.8552,472674,17652,473Jun 26 05:16 PM
MOTT DAVID MDirectorJun 25Sale13.3152,472698,649104,945Jun 26 05:16 PM
Agarwal ShefaliChief Medical OfficerJun 14Sale11.971,19514,30435,699Jun 17 05:18 PM
Beaulieu JosephCorporate ControllerJun 13Sale12.102032,456497Jun 14 06:56 PM
Bazemore Robert BPresident & CEOJun 13Sale12.102,07425,09584,994Jun 14 06:53 PM
Ros MatthewSee RemarksJun 13Sale12.101,18514,33939,032Jun 14 06:54 PM